Vlad Hogenhuis, Merck
S
Vlad Hogenhuis
General Manager for Neuroscience, Dermatology, and Ophthalmology, Merck
RECRUITED BY: Merck CEO Roy Vagelos
EXECS NEED: The courage to do what's right
I got a call from Dr. Vagelos, with the opportunity to be part of his mission" is how Vlad Hogenhuis, MD, introduces his 14-year career at Merck. Hogenhuis was getting a Wharton MBA at the time, but he has pharma in his blood. Born in the Netherlands to a long line of physicians—his father developed a migraine drug—he practiced medicine for four years before deciding to jump to industry.
Vlad Hogenhuis
He's climbed the Merck ladder by crossing from managing to managed care to licensing to R&D strategy. "I had a broad view early on," he says. Under CEO Dick Clark's new model integrating clinical and commercial, he directs both the late-stage pipeline and global marketing for a $1.7 billion three-disease franchise. "I have end-to-end accountability," he says. "There's full alignment of what the sales force does and what we do in marketing and even in Phase III."
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
